Clinical outcome of 36 male patients with primary urethral carcinoma: a single center experience
Yuvaraja B Thyavihally1, Hemant B Tongaonkar, Shyam K Srivastava
1Department of Urologic Oncology, Tata Memorial Hospital, Mumbai, India. tbyraja@rediffmail.com
Aim:
Retrospective analysis of male urethral carcinoma to assess the best therapeutic approach to the management of this tumor.
Methods:
A review of 36 cases of male urethral carcinoma diagnosed and treated at our center was performed. Clinical features, treatment modality and outcomes were analysed.
Results:
The overall median survival time was 55.16 months. The 5-year overall and disease-free survival rate for the cohort was 49% and 23%, respectively. The 5-year survival is 67% for low-stage versus 33% for high-stage tumors and is significantly different (P = 0.001). The survival was 72% for tumors of the distal urethra versus 36% for tumors of the proximal, with a P-value of 0.02.
Conclusion:
The tumor location and clinicopathological stage were the most important predictors of the disease-free and overall survival. Multimodal approach is necessary for achieving local control especially for proximal and higher stage tumors.
